July 31, 2025, NEW YORK – The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But ...
Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results